Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2002-04-23
2004-05-04
Jones, Dwayne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
06730665
ABSTRACT:
TECHNICAL FIELD
The invention relates to killing bone cancer cells and treating bone cancers.
BACKGROUND
Osteosarcoma is a malignant tumor of bone, which is most prevalent in adolescents and young adults. Osteosarcoma accounts for approximately 5% of the tumors in childhood and 80% of these tumors originate around the knee. The prognosis is often poor and within 1 year after commencing definitive therapy, about 30% of patients diagnosed with osteosarcoma will develop lung metastasis. The prognosis appears to be determined by the site of metastases and surgical resectability of the metastatic disease, either at diagnosis or following a variable period of chemotherapy. Patients who have complete surgical ablation of the primary and metastatic tumor (when confined to the lung) following chemotherapy may attain long-term survival, although event-free survival remains about 20% for patients with metastatic disease at diagnosis. Patients developing recurrent disease often have a poor prognosis and die within 1 year of the development of metastatic disease. Chemotherapy is often ineffective, resulting in a high mortality rate. Hence, it is important that new therapeutic approaches are evaluated for this malignant disease.
SUMMARY
The invention is based on the discovery that 2-methoxy estradiol (2ME) is cytotoxic to osteosarcoma cells in vitro and can reduce longitudinal bone growth rate and growth plate thickness in animals. Thus, the invention provides methods for treating bone cancers and methods for killing bone cancer cells, including osteosarcomas and chondrosarcomas.
In one aspect, the invention features a method for treating bone cancer in a patient. The method includes administering an amount of 2ME to the patient, wherein the amount of 2ME is cytotoxic to bone cancer cells. The bone cancer can be an osteosarcoma or a chondrosarcoma.
The invention also features a method for killing bone cancer cells. The method includes contacting the bone cancer cells with an amount of 2ME, wherein the amount of 2ME is cytotoxic to the bone cancer cells. The bone cancer cells can be human cells, osteosarcoma cells, or chondrosarcoma cells. The cells can be contacted in vitro or in vivo.
In another aspect, the invention features use of 2ME in the manufacture of a medicament for treatment of bone cancer.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
REFERENCES:
patent: 5643900 (1997-07-01), Fotsis et al.
patent: 5958892 (1999-09-01), Mukhopadhyay et al.
patent: WO 98/04291 (1998-02-01), None
Dorlands's Illustrated Medical Dictionary, 28thEdition, p. 1485, 1994.*
Borke et al., “Epitopes of the Human Erythrocyte Ca2+-Mg2+ATPase Pump in Human Osteoblast-Like Cell Plasma Membranes,”J. Clin. Endocrin. Metab., 1988, 67(6):1299-1304.
Fajardo et al., “A comparative study of the effects of genistein and 2-methoxyestradiol on the proteolytic balance and tumour cell proliferation,”Br. J. Cancer, 1999, 80(1/2):17-24.
He and Cushman, “A Versatile Synthesis of 2-Methoxyestradiol, an Endogenous Metabolite of Estradiol Which Inhibits Tubulin Polymerization by Binding to the Colchicine Binding Site,”Bioorganic&Medicinal Chemistry Letters, 1994, 4(14):1725-1728.
Himelstein, “Osteosarcoma and other bone cancers,”Curr. Opin. Oncol., 1996, 10:326-333.
Lynch et al., “Apoptosis During Bone-Like Tissue Development In Vitro,”J. Cell. Biochem., 1998, 68:31-49.
Merriam et al., “Comparative Properties of the Catechol Estrogens, I: Methylation by Catechol-O-Methyltransferase and Binding to Cytosol Estrogen Receptors,”Steroids, 1980, 36:1-11.
Oltvai et al., “Bcl-2 Heterodimerizes In Vivo with a Conserved Homolog, Bax, That Accelerates Programed Cell Death,”Cell, 1993, 74:609-619.
Turner et al., “Differential Responses of Estrogen Target Tissues in Rats Including Bone to Clomiphene, Enclomiphene, and Zuclomiphene,”Endocrinology, 1998, 139(9):3712-3720.
Wang and Cushman, “An Optimized Synthesis of 2-Methoxyestradiol, a Naturally Occurring Human Metabolite with Anticancer Activity,”Synthetic Comm., 1998, 28(23):4431-4437.
Fotsis et al., “The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth,”Nature, 1994, 36:237-239.
Maran et al., “2-Methoxyestradiol Induces Interferon Gene Expression and Apoptosis in Osteosarcoma Cells,”Bone, 2002, 30:393-398.
LaVallee et al., “2-Methoxyestradiol Up-Regulates Death Receptor 5 and Induces Apoptosis through Activation of the Extrinsic Pathway,”Cancer Research, 2003, 63:468-475.
“Soft Tissue Sarcomas: Questions and Answers, Cancer Facts 6.12”, 2000, National Cancer Institute website http://cis.nci.nih.gov/fact/6_12.htm, 7 pps.
Cotran et al.,Pathologic Basis of Disease, Sixth Edition, 1999, W.B. Saunders Company, pp. 1240-1242.
Maran Avudaiappan
Turner Russell T.
Fish & Richardson P.C. P.A.
Jones Dwayne C.
Mayo Foundation for Medical Education and Research
LandOfFree
Treatment of bone cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of bone cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of bone cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3225373